Piper Sandler Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT - Get Free Report) had its target price dropped by equities researchers at Piper Sandler from $12.00 to $8.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Piper Sandler's price objective would suggest a potential upside of 46.92% from the company's previous close.

HCAT has been the topic of several other reports. Canaccord Genuity Group dropped their price target on shares of Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, January 21st. Stephens increased their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an "equal weight" rating in a research note on Thursday, November 14th. Citigroup dropped their price target on shares of Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. KeyCorp upgraded shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 target price on the stock in a research report on Wednesday, January 8th. Finally, Royal Bank of Canada lowered their price objective on shares of Health Catalyst from $9.00 to $7.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $10.20.

Health Catalyst Stock Down 1.9 %

Shares of HCAT stock traded down $0.11 during trading hours on Tuesday, reaching $5.45. 340,641 shares of the stock were exchanged, compared to its average volume of 769,712. The firm has a market capitalization of $331.33 million, a P/E ratio of -4.04 and a beta of 1.34. Health Catalyst has a 12-month low of $5.32 and a 12-month high of $10.14. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The business's fifty day moving average is $6.58 and its two-hundred day moving average is $7.36.

Insider Transactions at Health Catalyst

In related news, General Counsel Benjamin Landry sold 19,268 shares of the business's stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the completion of the transaction, the general counsel now owns 72,250 shares of the company's stock, valued at approximately $601,120. The trade was a 21.05 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the business's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $5.76, for a total transaction of $30,003.84. Following the completion of the transaction, the chief operating officer now directly owns 86,044 shares of the company's stock, valued at $495,613.44. The trade was a 5.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,169 shares of company stock valued at $629,068 in the last 90 days. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Health Catalyst

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HCAT. Quantbot Technologies LP purchased a new stake in Health Catalyst in the 4th quarter valued at about $29,000. Quest Partners LLC purchased a new stake in Health Catalyst in the 3rd quarter valued at about $34,000. nVerses Capital LLC purchased a new stake in Health Catalyst in the 3rd quarter valued at about $59,000. Aquatic Capital Management LLC purchased a new stake in shares of Health Catalyst during the 4th quarter worth about $63,000. Finally, Stoneridge Investment Partners LLC purchased a new stake in shares of Health Catalyst during the 4th quarter worth about $77,000. Hedge funds and other institutional investors own 85.00% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.